Barclays
ACRS icon

Barclays’s Aclaris Therapeutics ACRS Stock Holding History

Barclays’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-100,000
Closed -$809K – 4506
2023
Q1 		$809K Buy
+100,000
New +$1.27M ﹤0.01% 2897

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Barclays's ACRS Position: Q1 2026 in Review

Barclays reduced its Aclaris Therapeutics (ACRS) stake by 85% in Q1 2026, selling an estimated $411K and leaving 21,508 shares worth $80.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4121.

Barclays first reported a position in ACRS in Q4 2015 and has held it in 39 quarters since. The position peaked at $1.6M in Q3 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Barclays held 21,508 shares of Aclaris Therapeutics worth $80.7K as of Q1 2026.
  • Barclays sold 121,906 Aclaris Therapeutics shares in Q1 2026, an estimated $411K.
  • Aclaris Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4121 holding.
  • Barclays first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 39 quarters since.
  • Barclays's Aclaris Therapeutics position peaked at $1.6M in Q3 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.